NextCure and Simcere start dose optimization for SIM0505 in platinum-resistant ovarian cancer.

NextCure and Simcere Zaiming have begun the dose optimization phase of their Phase 1 trial for SIM0505, an antibody drug conjugate targeting platinum-resistant ovarian cancer. This step aims to finalize dosing and reduce risks before larger registrational studies. The companies are expanding clinical trial sites in the U.S., China, Canada, and Europe to accelerate development. Phase 1 data will be presented at the ASCO 2026 conference, highlighting progress in this promising cancer therapy.